What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Mark G. Kris focuses on Lung cancer, Internal medicine, Oncology, Cancer and Adenocarcinoma.
His Lung cancer study combines topics from a wide range of disciplines, such as Surgery, Radiation therapy, Cancer research and Performance status.
In Internal medicine, Mark G. Kris works on issues like Gastroenterology, which are connected to Docetaxel.
His Oncology research integrates issues from Targeted therapy, Carcinoma, Disease and Clinical trial.
As part of one scientific family, Mark G. Kris deals mainly with the area of Cancer, narrowing it down to issues related to the MEDLINE, and often Emergency medicine, Intensive care medicine and Common Terminology Criteria for Adverse Events.
His research integrates issues of Mutation, KRAS, Lung, Exon and Stage in his study of Adenocarcinoma.
His most cited work include:
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib (3644 citations)
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain (2867 citations)
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial (2280 citations)
What are the main themes of his work throughout his whole career to date?
Mark G. Kris mostly deals with Internal medicine, Oncology, Lung cancer, Chemotherapy and Cancer research.
His studies link Gastroenterology with Internal medicine.
His studies examine the connections between Oncology and genetics, as well as such issues in Docetaxel, with regards to Vinorelbine.
His Lung cancer research incorporates elements of Cancer, Carcinoma and Clinical trial.
His Chemotherapy research incorporates themes from Anesthesia, Vomiting and Toxicity.
His Cancer research research incorporates themes from Mutation, Tyrosine kinase, Drug resistance and Exon.
He most often published in these fields:
- Internal medicine (59.00%)
- Oncology (48.71%)
- Lung cancer (44.19%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (59.00%)
- Oncology (48.71%)
- Lung cancer (44.19%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Oncology, Lung cancer, Lung and Cancer research.
His biological study spans a wide range of topics, including Immunohistochemistry, Phases of clinical research, Atezolizumab, Hazard ratio and Stage.
His Lung cancer research is multidisciplinary, relying on both Cancer, Targeted therapy, Adenocarcinoma and Mutation, KRAS.
In his research on the topic of Cancer, Cohort is strongly related with Carcinoma.
His studies in Cancer research integrate themes in fields like Tyrosine kinase, Mutant, Exon, Drug resistance and Osimertinib.
He interconnects Erlotinib and Epidermal growth factor receptor in the investigation of issues within Mutant.
Between 2015 and 2021, his most popular works were:
- Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial (820 citations)
- Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment (654 citations)
- Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. (530 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
His primary areas of investigation include Lung cancer, Internal medicine, Oncology, Cancer and Cancer research.
His Lung cancer research integrates issues from Mutation, KRAS, Targeted therapy, Exon and Adenocarcinoma.
His research in Oncology intersects with topics in Etoposide, Prospective cohort study, Surgery and Toxicity.
His Cancer research incorporates elements of Genotyping, Adverse effect, Immunology and Retrospective cohort study.
His Cancer research study integrates concerns from other disciplines, such as Clinical trial, Navitoclax, Kinase, Drug resistance and Osimertinib.
His research investigates the connection with Erlotinib and areas like Adjuvant which intersect with concerns in Epidermal growth factor receptor and Gastroenterology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
